Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
news

BioNTech to support trial access for cancer immunotherapies

5
SHARES

Signing of a major agreement between BioNTech SE and the UK government for cancer trials means more patients could access personalised immunotherapies.

BioNTech to support trial access for cancer immunotherapies

BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Signing of this agreement builds on a memorandum of understanding signed in January. The partnership will provide cancer patients with improved access to the latest cancer trials and therapies currently being developed.

This follows the government’s response to a review of clinical trials in May, plus a £121 million commitment towards improving and speeding up commercial clinical trials, including delivering a comprehensive and mandatory national approach to contracting.

Could BioNTech’s new partnership accelerate personalised mRNA therapy trials?

Deemed a “landmark new agreement” by UK Prime Minister Rishi Sunak, the UK-based clinical trials will focus on personalised mRNA-based cancer immunotherapies.

BioNTech SE has already begun conducting clinical trials in the UK. Further trials will be launching although most patients are expected to be enrolled from 2026 onwards.

Developing the innovative cancer immunotherapies

To help deliver this development of these cancer immunotherapies, BioNTech plans to set up a regional hub in England and new laboratories, expected to have a capacity for over 70 scientists in Cambridge.

The Cancer Vaccine Launch Pad (CVLP), a new partnership led by NHS England, will create a database of eligible NHS cancer patients who will be offered the choice to take part in personalised cancer vaccine trials. The project aims to help patients with early and late-stage cancers. If successfully developed, this means cancer vaccines could become part of standard care.

Therefore, patients will be given “the earliest possible access to cutting-edge technology that has the potential to change cancer care forever,” stated Amanda Pritchard, Chief Executive of the NHS.

“We are truly honoured to be an integral part of this landmark partnership… If successful, this collaboration has the potential to improve outcomes for patients with cancer not just in the UK, but also worldwide,” Professor Uğur Şahin, Chief Executive Officer and co-founder of BioNTech responded.

Share via
Share via